Detailed Scientific Program

Preliminary Program

We are delighted to present the preliminary program of AMP Europe 2020!

----
5 General Session8 Breakout Session6 Industry Symposium4 Abstract Session
TIMESESSION
09:00 am
-
10:45 am
General Session 1 (Solid Tumors)
Gene Fusions: An Emerging Target in Cancer Diagnostics and Treatment
ModeratorsTBA
Session
Description:
Gene fusions have been reported across different types of malignancies and have recently emerged as new targets for cancer therapy. There are several approaches available for fusion detection, including conventional techniques, targeted NGS and high-scale sequencing. This session will discuss new ESMO recommendations on the methods for detection of NTRK and other fusions in clinical practice and will review utility of high scale sequencing (RNA-seq) for detection of fusions.
Session
Objectives:
After this session, participants will be able to:
• Discuss the importance of gene fusions for cancer diagnosis and treatment.
• Identify the technical issues associated with detection of gene fusions in different sample types.
• Understand the methodologies for detection of fusions in clinical setting.
09:15 am
-
10:00 am
ESMO Guidelines and TRK Algorithm in Cancer
Frédérique Penault-Llorca (Clermont-Ferrand, France)
10:00 am
-
10:45 am
High Scale Sequencing (RNA-Seq) for Fusion Detection
Felix Sahm (Heidelberg, Germany)
10:45 am
-
11:15 am
COFFEE BREAK
11:15 am
-
12:45 pm
General Session 2 (Informatics)
Findings in Population Studies: A European View
ModeratorsTBA
Session
Description:
While biobanking samples for research studies has been a long-standing resources at many institutions, these have not been focused on doing this at a national scale nor with an eye toward clinical impact. Many European nations have taken a lead role in demonstrating the benefits and challenges of implementing large population studies within a national cohort and with a specific focus in genomics. In this session we will hear from some of the population studies at the forefront of implementing genomic medicine within a national infrastructure.
Session
Objectives:
After this session, participants will be able to:
• Understand the technical and logistical considerations when implementing a population level genomic study
• Examine how genetic risk information augments and modifies the effects of the traditional risk factors
• Evaluate the approaches and outcomes when providing genetic risk information to participants
11:15 am
-
11:45 am
Genetic and Clinical Risk of Common Complex Diseases in FinnGen Study
Samuli Ripatti (Helsinki, Finland)
11:45 am
-
12:15 pm
Return of Data Activities in Population-based Biobank: Current Experience and Implications for Personalized Prevention on a National Scale
Neeme Tõnisson (Tartu, Estonia)
12:15 pm
-
12:45 pm
Reassessing the Penetrance and Pathogenicity of Monogenic Disease Genes in a Population Setting
Mike Weedon (Exeter, United Kingdom)
12:45 pm
-
02:00 pm
LUNCH
02:00 pm
-
03:00 pm
Abstract Session
Selected Genetics Abstracts
Moderators:TBA
Session
Description:
Oral Presentations from Abstracts
Session
Objectives::
TBA
02:00 pm
-
02:15 pm
Molecular Characterization of Nephrosphere-Derived PKHhigh/CD133+/CD24- Stem-Like Cells Evidenced Possible New Markers for Renal Stem Cells in Situ Identification
Silvia Bombelli (Monza, Italy)
02:15 pm
-
02:30 pm
Benchmarking an Artificial Intelligence Method for Fast Diagnosis of Rare Genetic Disease
Eric Duncavage (St. Louis, United States)
02:30 pm
-
02:45 pm
Characterization of a Rare / Varying Clinical Consequence CFTR Variants W57G/A234D CFTR Genotype and Theratyping Using Rectal Organoids
Claudio Sorio (Verona, Italy)
02:45 pm
-
03:00 pm
The Link between Sleep Duration and Telomere Length: An Exploratory Study in Sicilian Centenarians
Anna Aiello (Palermo, Italy)
02:00 pm
-
03:00 pm
Abstract Session
Selected Hematopathology Abstracts
ModeratorsTBA
Session
Description:
Oral Presentations from Abstracts
Session
Objectives:
TBA
02:00 pm
-
02:15 pm
ChromoSeq: WGS-based Karyotyping for Hematologic Malignancies
Eric Duncavage (St. Louis, United States)
02:15 pm
-
02:30 pm
Whole Exome Sequencing Data Mining for Germline Genetic Predisposition in Childhood Hematologic Malignancies
Heather E. Williams (New York, United States)
02:30 pm
-
02:45 pm
Identification and Management of Myeloid Neoplasm-Associated Germline Variants after Diagnostic Somatic Next Generation Sequencing
Elizabeth M. Azzato (Cleveland, United States)
02:45 pm
-
03:00 pm
Myeloma-Induced Glutamine Depletion Inhibits Osteoblast Differentiation by Limiting Asparagine Availability: a Possible Metabolic Mechanism for Bone Lesions
Martina Chiu (Parma, Italy)
03:15 pm
-
04:15 pm
Industry Symposium
Please click here to see the Industry Symposium
03:15 pm
-
04:15 pm
Industry Symposium
Please click here to see the Industry Symposium
04:15 pm
-
04:45 pm
COFFEE BREAK
04:45 pm
-
05:45 pm
Breakout Session 1 (Solid Tumors)
Future of NGS in Clinical Oncology
ModeratorsTBA
Session
Description:
Next generation sequencing and other molecular techniques are routinely used in precision oncology for informing patient management. This session will discuss several molecular techniques that can be utilized for diagnosis, prognostication and treatment of cancer patients, including high-scale methylation profiling for classification of tumors and the role of NGS in systemic treatment of patients with advanced cancers.
Session
Objectives:
After this session, participants will be able to:
• Describe the utility of DNA methylation-based classification as a novel approach for tumor diagnosis.
• Discuss the different types of tumor-specific genetic alterations and their role in selection of therapy for patients with advanced cancers.
• Evaluate the role of targeted NGS and high-scale sequencing in routinely obtained tumor samples.
04:45 pm
-
05:15 pm
DNA Methylation Based Tumor Classification
Andreas von Deimling (Heidelberg, Germany)
05:15 pm
-
05:45 pm
Molecular Screening of Advanced Cancer Patients
Marjolijn Ligtenberg (Nijmegen, The Netherlands)
04:45 pm
-
05:45 pm
Breakout Session 2 (Genetics)
Exploring Informatics: Quality Metrics to Artificial Intelligence
ModeratorsTBA
Session
Description:
Advanced diagnostics for rare diseases require informatics to manage the large amount of data generated. In massively parallel sequencing (MPS), informatics is used to assess data quality, applying numerous metrics to alignment and variant calling. Artificial intelligence (AI) and machine learning applications include variant prioritization and classification. This session will explore how informatics is applied to clinical testing and how to assess AI applications to validate them for clinical care.
Session
Objectives:
After this session, participants will be able to:
• Describe metrics used to assess MPS data quality
• Discuss course of action when metrics trend away from expected values
• List approaches to validate AI applications
04:45 pm
-
05:15 pm
A Deep Dive into Quality Metrics – From Sample to Report
Honey V. Reddi (Wisconsin, USA)
05:15 pm
-
05:45 pm
Artificial Intelligence for Variant Prioritization
Frederico Cabitza (Milan, Italy)
05:45 pm
-
07:00 pm
Welcome Reception
07:00 pm
-
07:45 pm
Industry Symposium
Please click here to see the industry Symposium
07:00 pm
-
07:45 pm
Industry Symposium
Please click here to see the industry Symposium
TIMESESSION
08:00 am
-
09:00 am
Breakout Session 3 (Informatics)
Approaches to Cutting Edge Somatic Testing
Moderators:TBA
Session
Description:
With the introduction of molecular technologies in disciplines like infectious diseases and oncology, quality assurance aspects and External Quality Assurance are essential performance criteria. The development of -international- standards, the implementation of the ISO-15189 guideline and the new European CE-IVD regulation, will be discussed.
Session
Objectives:
After this session, participants will be able to:
• Evaluate the computational approaches used in the newest methodologies for somatic testing
• Understand the challenges of implementing these newer testing modalities in a clinical laboratory
• Interpret the findings from these assays and computational approaches and demonstrate their utility in the clinical testing landscape
08:00 am
-
08:30 am
TMB Approaches
Albrecht Stenzinger (Heidelberg, Germany)
08:30 am
-
09:00 am
Liquid Biopsy/cfDNA Informatics
Nitzan Rosenfeld (Cambridge, United Kingdom)
08:00 am
-
09:00 am
Breakout Session 4 (Infectious Diseases)
Quality Assurance in Molecular Testing
Moderators:TBA
Session
Description:
Over the last few years, somatic variant testing has rapidly progressed from single variant assays to large panels and even exome/genome testing. As this testing has progressed, so too has the ability to identify findings and patterns that have not been considered previously. In this session, the audience will hear about some of the most cutting edge somatic testing assays, including tumor mutational burden, microsatellite instability, liquid biopsies, and cell-free circulating tumor DNA. Specifically, this session will focus on the complex informatic approaches required to implement these assays successfully in a clinical laboratory.
Session
Objectives:
After this session, participants will be able to:
• Apply performance criteria to assist in introducing molecular testing
• Interpret the impact of regulations like ISO15189 and the CE-IVD directive on molecular testing
• Employ criteria to introduce new technologies to answer questions in our clinical setting
08:00 am
-
08:30 am
TBA
Paul Wallace (Glasgow, United Kingdom)
08:30 am
-
09:00 am
QA in Cancer Diagnostics: Consistency and Reproducibility of Next-generation Sequencing in Cytopathology
Giancarlo Troncone, MD, PhD, University of Naples "Federico II", Naples, Italy
09:00 am
-
09:45 am
COFFEE BREAK
09:45 am
-
10:45 am
Breakout Session 5 (Solid Tumors)
Translating Cancer Genomics into Precision Medicine with Artificial Intelligence
Moderators:TBA
Session
Description:
Precision medicine in the area of oncology relies on the accurate interpretation of genomic variants to facilitate tumor diagnosis, prognosis, and selection of individualized therapy. Recent guidelines for variant interpretation and reporting provided some standardization, however more tools and resources are needed for evaluating variants and their relevance in a clinical setting. This session will focus on a harmonized approach for clinical interpretations of cancer genomic variants.
Session
Objectives:
After this session, participants will be able to:
• Describe the challenges in clinical interpretation of genomic variants.
• Discuss an importance of artificial intelligence in assisting with the interpretation of cancer genomic variants.
• Identify the future role of sharing variant interpretation data and availability of meta-knowledgbases.
09:45 am
-
10:45 am
TBA
Olivier Elemento (New York, USA)
09:45 am
-
10:45 am
Breakout Session 6 (Hempath)
Germline Mutations Predisposing to Hematological Malignancies
Moderators:TBA
Session
Description:
The clinical phenotype of genetic diseases is sometimes very mild, but causative mutations can expose patients to the risk of developing potentially deadly diseases in childhood or adulthood. Inherited thrombocytopenias are a typical example of this phenomenon.
Session
Objectives:
After this session, participants will be able to:
• Recognize that while some hematological malignancies with germline predisposition occur without a pre-existing disorder or organ dysfunction, others instead have a preexisting platelet disorder or are characterized by disfunction of other organs.
• Recognize that hematological neoplasms are not always sporadic but could occur because of genetic predisposition and that family history can be unremarkable due to incomplete penetrance.
09:45 am
-
10:15 am
Predisposition to Myeloid Neoplasms
Charlotte Niemeyer (Freiburg, Germany)
10:15 am
-
10:45 am
When Mild Inherited Disorders Underlie the Risk of Acquiring Life-threatening Diseases
Carlo Balduini, University of Pavia, Pavia, Italy
11:00 am
-
12:00 pm
Abstract Session
Selected Solid Tumor Abstracts
Moderators:TBA
Session
Description:
Oral Presentations from Abstracts
Session
Objectives:
TBA
11:00 am
-
11:15 am
Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the FOLLOW IT Assay from the Exactis Trial (NCT00984048)
Melissa K. McConechy, Contextual Genomics, Vancouver, Canada
11:15 am
-
11:30 am
Towards Internationally Agreed Units for Cancer Genomic Measurement Worldwide: The Role of WHO International Standards
Angela Pia Sanzone, National Institute for Biological Standards and Control, Potters Bar, United Kingdom
11:30 am
-
11:45 am
SureMASTRr HRR Assay Is an Extensive Research Solution for SNV, Indel and CNV/CNA Detection in 17 HRR-Related Target Genes in Blood- and FFPE-Derived DNA
Karolien Bettens, Agilent Technologies, Niel, Belgium
11:00 am
-
12:00 pm
Abstract Session
Selected Informatics & Other Abstracts
Moderators:TBA
Session
Description:
Oral Presentations from Abstracts
Session
Objectives:
TBA
11:45 am
-
12:00 pm
Difficulties in Analyzing Microsatellite Instability in Endometrial Cancer- the Pros and Cons of Four Different PCR Based Testing Approaches
Janna Siemanowski, University Hospital Cologne, Cologne, Germany
11:00 am
-
11:15 am
RNA Sequencing Using Non-Cell Block Cytology Slides Demonstrates Specific Advantages over Formalin Fixed Paraffin Embedded Specimens
Nikoletta Sidiropoulos, University of Vermont Health Network, Burlington, United States
11:15 am
-
11:30 am
Diabetes-Like Environment Affects Epicardial Adipose Tissue-Derived Mesenchymal Stem Cell Fate
Serena Cabaro, University of Naples “Federico II”, Naples, Italy
11:30 am
-
11:45 am
Dynamic Encryption and Watermarking of Genomic Sequencing Data to Facilitate Privacy-Preserving Ownership-Based Data Governance
Xiaowu Gai, Children's Hospital of Los Angeles, Los Angeles, United States
11:45 am
-
12:00 pm
Building Scalable and Robust Informatics Systems for Clinical Genomic Assays in the Precision Medicine Era
Andrea Sboner, Weill Cornell Medicine, New York, United States
12:00 pm
-
1:15 pm
LUNCH
1:15 pm
-
2:15 pm
Industry Symposium
Please click here to see the Industry Symposium
1:15 pm
-
2:15 pm
Industry Symposium
Please click here to see the Industry Symposium
3:15 pm
-
4:00 pm
COFFEE BREAK
04:00 pm
-
05:30 pm
General Session 3 (Infectious Diseases)
Metagenomics and NGS in Clinical Microbiology
Moderators:TBA
Session
Description:
The session will provide information about the use and implementation of next generation sequencing and metagenomics to address questions related to infection control, epidemiology and antimicrobial resistance, as well as the ability to detect unknown or new pathogens in clinical samples. Challenges relating to bioinformatics and the development of a workflow/pipeline, will be discussed.
Session
Objectives:
After this session, participants will be able to:
• Apply NGS/metagenomics to predict antimicrobial resistance patterns.
• Introduce infection control measurements based on data derived through Next Generation Sequencing.
• Formulate a clinical diagnosis based on NGS/metagenomics data in relation to clinical findings.
04:45 pm
-
05:30 pm
Using NGS in Looking for Pathogens
Charles Chiu (San Francisco, USA)
04:45 pm
-
05:30 pm
Use of NGS in Infection Control and the Detection of Resistance Genes
John Rossen (Groningen, The Netherlands)
05:30 pm
-
06:10 pm
Industry Symposium
Please click here to see the Industry Symposium
TIMESESSION
08:00 am
-
09:30 am
General Session 4 (Genetics)
STAT: Critical Care Genomics
ModeratorsTBA
Session
Description:
Clinical genome and exome sequencing is available for rapid diagnoses in critical care settings (neonatal or pediatric intensive care). The utility of genomic sequencing approaches is demonstrated by providing a molecular diagnosis which in turn may indicate a treatment, intervention or management. This session will discuss methods and outcomes used to evaluate utility of clinical genomes/exomes.
Session
Objectives:
After this session, participants will be able to:
•Define types of clinical utility
•List categories of data needed to demonstrate clinical utility
•Illustrate challenges with providing rapid turn-around of genomic results
08:00 am
-
08:45 am
Indications and Utility of Rapid Genomes in ICU Settings
Stephen Kingsmore (San Diego, USA )
08:45 am
-
09:30 am
Clinical Utility of Genomic Sequencing in a Newbornand Neonatal Intensive Care Settings
Christine Eng (Baylor, USA)
09:30 am
-
10:15 am
COFFEE BREAK
10:15 am
-
11:15 am
Industry Symposium
Please click here to see the Industry Symposium
11:15 am
-
12:15 am
Industry Symposium
Please click here to see the Industry Symposium
12:15 pm
-
01:15 pm
LUNCH
01:15 pm-
02:15 pmr
Breakout Session 7 (Hempath)
Liquid Biopsies for Lymphomas
Moderators:TBA
Session
Description:
The session will discuss the dynamics of cell free tumor DNA (ctDNA) in lymphoma patients, and its applications for non-invasive diagnosis, identification of actionable mutations, accurate monitoring and identification of resistant mutations.
Session
Objectives:
After this session, participants will be able to:
•Learn how the amount of ctDNA differ in lymphoma patients varies with the type of lymphoma, and with disease status
•Learn about applications of ctDNA sequencing in patients with lymphoma
01:15 pm
-
02:15 pm
Liquid Biopsy for B-cell non-Hodgkin Lymphoma
Gianluca Gaidano (Novara, Italy)
01:15 pm
-
02:15 pm
Breakout Session 8 (Genetics)
What's Next in Clinical Genomics? Supplementing Genome/Exome Analysis
Moderators:TBA
Session
Description:
Clinical exome/genome testing provides a molecular diagnosis in approximately 30-60% of cases, depending on the indications for testing, clinical symptoms and family history. For the remaining cases in which no potential diagnosis is identified, the answer may or may not be in the genome. What can be done for patients in which a molecular diagnosis is not made? What are the next approaches to understanding genomic variation and improving diagnostics? This session will explore additional testing such as transcriptomes and long read technologies to supplement a “negative” genome.
Session
Objectives:
After this session, participants will be able to:
•List genomic regions difficult to sequence or interpret with current short read technology
•Contrast advantages and challenges of transciptome sequencing in clinical settings
•Discuss genetic variations that can be identified by long read technologies
01:15 pm
-
01:45 pm
The Diagnosis of Mendelian Disorders by an Integrative “multi-omic” Approach
Holger Proksich (Munich, Germany)
01:45pm
-
02:15 pm
Identification of Hidden Structural Variants with Long-Read Sequencing and Genome Imaging
Alexander Hoischen (Nijmegen, The Netherlands)
02:15 am
-
02:45 am
COFFEE BREAK
02:45 pm
-
03:45 pm
General Session 5 (HempPath)
Innate Immunity. Inflammation and Cancer: Double Edged Swords
02:45 pm
-
03:45 pm
Innate Immunity, Inflammation and Cancer: Double Edged Swords
Alberto Montovani, MD, Humanitas University, Milan, Italy
03:45 pm
-
04:45 pm
General Session 6 (TBD)
SIPMet Session - Deregulation & Targeting in Cancer
ModeratorsTBA
Session
Description:
Cancer is characterized by both genetic and epigenetic alterations. While cancer driver mutations and copy-number alterations have been studied at a systems-level, relatively little is known about the systems-level patterns exhibited by their epigenetic counterparts. In this section speakers will perform a pan-cancer wide systems-level analysis, mapping candidate cancer-driver DNA methylation (DNAm) alterations onto a human interactome. The invited speakers demonstrate that functional DNAm alterations in cancer tend to map to nodes of lower connectivity and inter-connectivity, compared to the corresponding alterations at the genomic level. There are findings that epigenetic alterations are relatively over-represented in extracellular and transmembrane signaling domains, whereas cancer genes undergoing amplification or deletion tend to be enriched within the intracellular domain.
Session
Objectives:
After this session, participants will be able to: The results suggest that epigenetic deregulation in cancer not only targets tissue-specific transcription factors, but also modulates signaling within the extra-cellular domain, providing novel system-level insight into the potential distinctive role of genetic and epigenetic alterations in cancer.
03:45 pm
-
04:45 pm
Targeting Epigenome in Cancer
Lucia Altucci (Naples, Italy)
03:45 pm
-
04:45 pm
Deregulation of Hedgehog Signaling in Cancer: Targeting Epigenetic and Metabolic Vulnerabilities
Gianluca Canettieri (Rome, Italy)
04:45 pm
-
05:00 pm
Award Recognition & Closing Remarks

*Please note that the schedule is subject to change.